18F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Martin H. Cherk; David P. Nadebaum; Thomas W. Barber; Paul Beech; Andrew Haydon; Kenneth S. Yap

doi:10.1111/1754-9485.13390

¹⁸F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Martin H. Cherk, David P. Nadebaum, Thomas W. Barber, Paul Beech, Andrew Haydon, Kenneth S. Yap

Research output: Contribution to journal › Article › Other › peer-review

27 Citations (Scopus)

Abstract

¹⁸F-FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with ¹⁸F-FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune-related adverse events (irAEs) can be detected on ¹⁸F-FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on ¹⁸F-FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression.

Original language	English
Pages (from-to)	483-494
Number of pages	12
Journal	Journal of Medical Imaging and Radiation Oncology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1111/1754-9485.13390
Publication status	Published - Jun 2022

Keywords

F-FDG PET
nuclear imaging
nuclear medicine
oncologic imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1754-9485.13390Licence: CC BY-NC-ND

Cite this

@article{fa8e25e2fa7c4c9cafdf759bd2f16ae4,

title = "18F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy",

abstract = "18F-FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with 18F-FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune-related adverse events (irAEs) can be detected on 18F-FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on 18F-FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression.",

keywords = "F-FDG PET, nuclear imaging, nuclear medicine, oncologic imaging",

author = "Cherk, \{Martin H.\} and Nadebaum, \{David P.\} and Barber, \{Thomas W.\} and Paul Beech and Andrew Haydon and Yap, \{Kenneth S.\}",

note = "Funding Information: Open access publishing facilitated by Monash University, as part of the Wiley - Monash University agreement via the Council of Australian University Librarians. Publisher Copyright: {\textcopyright} 2022 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley \& Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.",

year = "2022",

month = jun,

doi = "10.1111/1754-9485.13390",

language = "English",

volume = "66",

pages = "483--494",

journal = "Journal of Medical Imaging and Radiation Oncology",

issn = "1754-9477",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - 18F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

AU - Cherk, Martin H.

AU - Nadebaum, David P.

AU - Barber, Thomas W.

AU - Beech, Paul

AU - Haydon, Andrew

AU - Yap, Kenneth S.

N1 - Funding Information: Open access publishing facilitated by Monash University, as part of the Wiley - Monash University agreement via the Council of Australian University Librarians. Publisher Copyright: © 2022 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.

PY - 2022/6

Y1 - 2022/6

N2 - 18F-FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with 18F-FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune-related adverse events (irAEs) can be detected on 18F-FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on 18F-FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression.

AB - 18F-FDG PET/CT scanning is routinely performed to stage and evaluate the treatment response in many malignancies. Immunotherapy is a rapidly growing treatment option for many cancers, and both clinicians and imaging specialists need to be familiar with 18F-FDG PET/CT imaging characteristics unique to patients on this type of treatment. In particular, many immune-related adverse events (irAEs) can be detected on 18F-FDG PET/CT and early accurate identification is critical to reduce treatment related morbidity and incorrect interpretation of malignant disease status. This pictorial essay reviews frequently encountered irAEs in clinical practice and their appearances on 18F-FDG PET/CT along with a brief discussion on pseudoprogression and hyperprogression.

KW - F-FDG PET

KW - nuclear imaging

KW - nuclear medicine

KW - oncologic imaging

UR - https://www.scopus.com/pages/publications/85125766051

U2 - 10.1111/1754-9485.13390

DO - 10.1111/1754-9485.13390

M3 - Article

C2 - 35191204

AN - SCOPUS:85125766051

SN - 1754-9477

VL - 66

SP - 483

EP - 494

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

IS - 4

ER -

¹⁸F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Monash Biomedical Imaging (MBI)

Cite this

18F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Equipment

Monash Biomedical Imaging (MBI)

Cite this

¹⁸F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy